Replimune Group & United States — Food and Drug Administration

Replimune Group: Replimune Group>>> is a biotechnology company whose melanoma therapy was twice rejected by the United States — Food and Drug Administration>>> under Marty Makary>>>'s leadership. News of Marty Makary>>>'s potential ouster caused its shares to rise.

United States — Food and Drug Administration: The United States — Food and Drug Administration>>> is the agency undergoing a significant leadership change with the planned ouster of its Commissioner Marty Makary>>>, which has led to low morale and high-profile departures.

Replimune Group: Replimune Group is a pharmaceutical company whose cancer drug rejection by the United States — Food and Drug Administration under Marty Makary's leadership was criticized by The Wall Street Journal.

United States — Food and Drug Administration: The United States — Food and Drug Administration is experiencing a leadership change with the resignation of its Commissioner, Marty Makary, and the appointment of Kyle Diamantas as acting chief. The agency has faced internal clashes, policy confusion, and criticism during Marty Makary's tenure.

Replimune Group: Replimune Group is the target of multiple class action lawsuits due to alleged false statements regarding its IGNYTE trial, which led to the United States — Food and Drug Administration deeming the trial inadequate.